This site is intended for healthcare professionals

FDA advisory committee recommends combination Cyramza + erlotinib to treat EGFR-positive NSCLC.- Eli Lilly

Read time: 1 mins
Published:28th Feb 2020
Eli Lilly and Company announced that a FDA Oncologic Drugs Advisory Committee (ODAC) voted 6-5 that Cyramza (ramucirumab) plus erlotinib demonstrated a favorable benefit/risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer (NSCLC), based on the results of the positive Phase III RELAY study. The ODAC considered the safety and efficacy data from the Phase III RELAY trial, which is the basis for the Cyramza supplemental Biologics License Application (sBLA) currently under review by the FDA. In the RELAY study, Cyramza, a VEGF receptor 2 antagonist, in combination with erlotinib, a globally approved EGFR-targeting tyrosine kinase inhibitor (TKI), demonstrated a statistically significant and clinically meaningful improvement in progression-free survival – the time patients live without their disease getting worse – compared to erlotinib alone. Median PFS on the Cyramza-plus-erlotinib arm was 19.4 months compared to 12.4 months on the placebo-plus-erlotinib arm, an improvement of seven months (HR 0.59; 95% CI, 0.46-0.79; P<0.0001). the safety profile observed in the relay study was consistent with what has been previously observed for cyramza in phase iii clinical trials and the established safety profile of erlotinib. the most common (>5% incidence) Grade greater than 3 adverse events occurring at a higher rate ( greater than 5% difference) on the Cyramza-plus-erlotinib arm compared to the placebo-plus-erlotinib arm were hypertension, dermatitis acneiform (an acne-like rash), and diarrhea. There is no cure for people with metastatic EGFR-mutated lung cancer and disease progression following acquired resistance remains a challenge. Most patients receive several lines of treatment and the therapeutic regimen prescribed for first-line treatment can impact a person's options for later lines of therapy. Globally, tyrosine kinase inhibitors (TKIs) – including erlotinib, which was used in the trial – are the current standard treatment option for EGFR-mutated NSCLC. There remains an ongoing need for additional first-line therapeutic options that provide clinically meaningful benefits – including delaying disease progression and use of chemotherapy as long as possible. Moreover, new treatment options could allow oncologists greater choice on how to use the available agents, in shared decision-making with their patients. Lilly has also made regulatory submissions outside the U.S. based on the RELAY data. In January 2020, the European Commission granted European Union approval for Cyramza in combination with erlotinib for the first-line treatment of adult patients with metastatic NSCLC with activating EGFR mutations. Lilly has submitted in Japan and expects regulatory action in the second half of 2020.
Condition: NSCLC / EGFR
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights